Current Report Filing (8-k)
July 02 2019 - 8:01AM
Edgar (US Regulatory)
UNITED STATES
SECURITIES AND EXCHANGE COMMISSION
Washington, D.C. 20549
FORM 8-K
Current Report
Pursuant to Section 13 or 15(d)
of the Securities Exchange Act of 1934
Date of Report (date of earliest event reported):
July 2, 2019
IOVANCE
BIOTHERAPEUTICS, INC.
(Exact Name of Registrant as Specified in Charter)
Delaware
|
(State of Incorporation)
|
|
001-36860
|
|
75-3254381
|
Commission File Number
|
|
(I.R.S. Employer Identification No.)
|
|
|
|
999 Skyway Road, Suite 150
|
|
|
San Carlos, California
|
|
94070
|
(Address of Principal Executive Offices)
|
|
(Zip Code)
|
|
|
|
(650) 260-7120
|
(Registrant’s Telephone Number, Including Area Code)
|
|
Check the appropriate box below if the Form 8-K filing is intended
to simultaneously satisfy the filing obligation of the registrant under any of the following provisions:
|
¨
|
Written communications pursuant to Rule 425 under
the Securities Act (17 CFR 230.425).
|
|
¨
|
Soliciting material pursuant to Rule 14a-12 under
the Exchange Act (17 CFR 240.14a-12).
|
|
¨
|
Pre-commencement communications pursuant to Rule 14d-2(b)
under the Exchange Act (17 CFR 240.14d-2(b)).
|
|
¨
|
Pre-commencement communications pursuant to Rule 13e-4(c)
under the Exchange Act (17 CFR 240.13e-4(c)).
|
Indicate
by check mark whether the registrant is an emerging growth company as defined in as defined in Rule 405 of the Securities Act of
1933 (§230.405 of this chapter) or Rule 12b-2 of the Securities Exchange Act of 1934 (§240.12b-2 of this chapter). Emerging
growth company
¨
If
an emerging growth company, indicate by check mark if the registrant has elected not to use the extended transition period for
complying with any new or revised financial accounting standards provided pursuant to Section 13(a) of the Exchange Act.
¨
Securities registered pursuant to Section 12(b) of the Act:
Title of each class
|
Trading Symbol(s)
|
Name of each exchange on which registered
|
Common stock, par value $0.000041666 per share
|
IOVA
|
The Nasdaq Stock Market, LLC
|
On July 2, 2019, Iovance Biotherapeutics,
Inc. (the “Company”) updated its corporate presentation that it uses for presentations at healthcare conferences and
to analysts, current stockholders, and others. A copy of the Company’s presentation that it intends to use at such events
is attached as Exhibit 99.1 and incorporated herein by reference.
On July 2, 2019, the Company issued a press
release announcing an update on regulatory matters following an End of Phase 2 Meeting with the U.S. Food and Drug Administration
regarding the Company’s autologous tumor-infiltrating lymphocyte (TIL) therapy candidate LN-145 in advanced cervical cancer.
The full text of the press release is attached hereto as Exhibit 99.2 and incorporated herein by reference.
|
Item 9.01.
|
Financial Statements and Exhibits.
|
(d) Exhibits.
SIGNATURES
Pursuant to the requirements of the Securities
Exchange Act of 1934, the Registrant has duly caused this Report to be signed on its behalf by the undersigned hereunto duly authorized.
Date: July 2, 2019
|
IOVANCE BIOTHERAPEUTICS,
INC.
|
|
|
|
|
|
|
|
|
By:
|
/s/
MARIA FARDIS
|
|
|
|
Maria Fardis, Chief Executive Officer
|
|
|
|
|
Iovance Biotherapeutics (NASDAQ:IOVA)
Historical Stock Chart
From Aug 2024 to Sep 2024
Iovance Biotherapeutics (NASDAQ:IOVA)
Historical Stock Chart
From Sep 2023 to Sep 2024